SE0104423D0 - Pregnane steroids and their use in the treatment of CNS disorders - Google Patents
Pregnane steroids and their use in the treatment of CNS disordersInfo
- Publication number
- SE0104423D0 SE0104423D0 SE0104423A SE0104423A SE0104423D0 SE 0104423 D0 SE0104423 D0 SE 0104423D0 SE 0104423 A SE0104423 A SE 0104423A SE 0104423 A SE0104423 A SE 0104423A SE 0104423 D0 SE0104423 D0 SE 0104423D0
- Authority
- SE
- Sweden
- Prior art keywords
- treatment
- cns disorders
- steroid
- substances
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
CA2468248A CA2468248C (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
US10/499,214 US7960367B2 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids and their use in the treatment of CNS disorders |
AU2002359202A AU2002359202C1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of CNS disorders |
CNA2009101459536A CN101601674A (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经系统功能紊乱的孕烷类固醇 |
DK02793723.4T DK1458399T3 (da) | 2001-12-27 | 2002-12-20 | Pregnansteroider til brug i behandlingen af CNS-sygdomme |
ES02793723T ES2394639T3 (es) | 2001-12-27 | 2002-12-20 | Esteroides de pregnano para utilización en el tratamiento de trastornos del CNS |
PCT/SE2002/002423 WO2003059357A1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
CNB028262751A CN100518741C (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经系统功能紊乱的孕烷类固醇 |
CNA2009101459540A CN101601675A (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经系统功能紊乱的孕烷类固醇 |
JP2003559519A JP2005519893A (ja) | 2001-12-27 | 2002-12-20 | Cns疾患の治療において使用するためのプレグナンステロイド |
EP10183670.8A EP2275109B1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of CNS disorders |
EP02793723A EP1458399B1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
AU2009201956A AU2009201956B2 (en) | 2001-12-27 | 2009-05-18 | Pregnane steroids for use in the treatment of CNS disorders |
AU2009201951A AU2009201951A1 (en) | 2001-12-27 | 2009-05-18 | Pregnane steroids for use in the treatment of CNS disorders |
JP2009256620A JP5289281B2 (ja) | 2001-12-27 | 2009-11-10 | Cns疾患の治療において使用するためのプレグナンステロイド |
US12/986,937 US8119619B2 (en) | 2001-12-27 | 2011-01-07 | Pregnane steroids and their use in the treatment of CNS disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0104423D0 true SE0104423D0 (sv) | 2001-12-27 |
Family
ID=20286518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
Country Status (10)
Country | Link |
---|---|
US (2) | US7960367B2 (sv) |
EP (2) | EP1458399B1 (sv) |
JP (2) | JP2005519893A (sv) |
CN (3) | CN101601675A (sv) |
AU (3) | AU2002359202C1 (sv) |
CA (1) | CA2468248C (sv) |
DK (1) | DK1458399T3 (sv) |
ES (1) | ES2394639T3 (sv) |
SE (1) | SE0104423D0 (sv) |
WO (1) | WO2003059357A1 (sv) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4914368B2 (ja) * | 2004-11-18 | 2012-04-11 | ウメクライン アーベー | Gaba−ステロイド拮抗剤およびcns疾患の治療のためのその使用 |
BR122013033954B8 (pt) | 2006-11-21 | 2021-05-25 | Umecrine Ab | novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção |
US20090269795A1 (en) * | 2007-03-09 | 2009-10-29 | The Research Foundation Of State University Of New York | Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
ES2566765T3 (es) | 2010-01-14 | 2016-04-15 | Asarina Pharma Ab | Una composición farmacéutica que contiene 3-beta-hidroxi-5-alfa-pregnan-20-ona con propiedades de almacenamiento y solubilidad mejoradas |
EP3170501B1 (en) * | 2011-05-20 | 2020-07-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonists of cb1 receptor |
RU2667065C2 (ru) | 2012-11-28 | 2018-09-14 | Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) | Производные прегненолона |
WO2015114308A1 (en) * | 2014-01-29 | 2015-08-06 | Umecrine Cognition Ab | Steroid compound for use in the treatment of hepatic encephalopathy |
JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
RU2019116165A (ru) * | 2017-01-09 | 2021-02-09 | Асарина Фарма Аб | Инъекционные суспензии |
WO2018147792A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment |
EP3579842A4 (en) | 2017-02-10 | 2020-12-23 | Asarina Pharma AB | 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS |
MX2020010219A (es) | 2018-04-05 | 2020-11-09 | Asarina Pharma Aps | Antagonistas de gaba-a para tratar trastornos por abstinencia de sustancia. |
WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083978A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5439900A (en) * | 1993-02-25 | 1995-08-08 | Bukusoglu; Cuneyt | Methods and compositions for providing analgesia and enhanced anesthesia |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
CN1255141A (zh) * | 1997-05-02 | 2000-05-31 | 美国家用产品公司 | 具有孕激素活性的5α-孕-16-烯-3β-醇-20-酮3-硫酸酯的盐 |
KR20010012157A (ko) * | 1997-05-02 | 2001-02-15 | 이곤 이 버그 | 프레그난-3-올-20-온 |
CA2289096A1 (en) * | 1997-05-02 | 1998-11-12 | Reinhold H. W. Bender | Pharmaceutically acceptable salts of 5alpha-pregnan-3beta, 16alpha-diol-20-one 3-sulfate useful as progestins and cns disorders |
EP1063999B1 (en) * | 1998-03-11 | 2005-10-26 | Torbjörn Backström | Epiallopregnanolone in the treatment of cns disorders |
EP1121376A1 (en) * | 1998-10-13 | 2001-08-08 | American Home Products Corporation | Pregnane glucuronides |
US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
-
2001
- 2001-12-27 SE SE0104423A patent/SE0104423D0/sv unknown
-
2002
- 2002-12-20 CN CNA2009101459540A patent/CN101601675A/zh active Pending
- 2002-12-20 ES ES02793723T patent/ES2394639T3/es not_active Expired - Lifetime
- 2002-12-20 AU AU2002359202A patent/AU2002359202C1/en not_active Ceased
- 2002-12-20 CN CNA2009101459536A patent/CN101601674A/zh active Pending
- 2002-12-20 EP EP02793723A patent/EP1458399B1/en not_active Expired - Lifetime
- 2002-12-20 US US10/499,214 patent/US7960367B2/en not_active Expired - Fee Related
- 2002-12-20 CN CNB028262751A patent/CN100518741C/zh not_active Expired - Fee Related
- 2002-12-20 CA CA2468248A patent/CA2468248C/en not_active Expired - Fee Related
- 2002-12-20 WO PCT/SE2002/002423 patent/WO2003059357A1/en active Application Filing
- 2002-12-20 EP EP10183670.8A patent/EP2275109B1/en not_active Expired - Lifetime
- 2002-12-20 JP JP2003559519A patent/JP2005519893A/ja active Pending
- 2002-12-20 DK DK02793723.4T patent/DK1458399T3/da active
-
2009
- 2009-05-18 AU AU2009201951A patent/AU2009201951A1/en not_active Abandoned
- 2009-05-18 AU AU2009201956A patent/AU2009201956B2/en not_active Ceased
- 2009-11-10 JP JP2009256620A patent/JP5289281B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-07 US US12/986,937 patent/US8119619B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2010065052A (ja) | 2010-03-25 |
ES2394639T3 (es) | 2013-02-04 |
EP1458399A1 (en) | 2004-09-22 |
US20050222099A1 (en) | 2005-10-06 |
CA2468248C (en) | 2011-08-16 |
AU2002359202C1 (en) | 2011-03-31 |
WO2003059357A1 (en) | 2003-07-24 |
CN1607954A (zh) | 2005-04-20 |
CN101601674A (zh) | 2009-12-16 |
AU2009201956A1 (en) | 2009-06-11 |
CN100518741C (zh) | 2009-07-29 |
AU2009201956A2 (en) | 2010-02-18 |
JP5289281B2 (ja) | 2013-09-11 |
JP2005519893A (ja) | 2005-07-07 |
CN101601675A (zh) | 2009-12-16 |
AU2009201956B2 (en) | 2010-11-25 |
EP2275109A3 (en) | 2011-10-12 |
US8119619B2 (en) | 2012-02-21 |
EP2275109B1 (en) | 2013-07-24 |
DK1458399T3 (da) | 2012-11-12 |
AU2009201951A1 (en) | 2009-06-04 |
AU2002359202A1 (en) | 2003-07-30 |
EP2275109A2 (en) | 2011-01-19 |
US7960367B2 (en) | 2011-06-14 |
CA2468248A1 (en) | 2003-07-24 |
US20110098259A1 (en) | 2011-04-28 |
AU2002359202B2 (en) | 2009-02-19 |
EP1458399B1 (en) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0104423D0 (sv) | Pregnane steroids and their use in the treatment of CNS disorders | |
WO2002058684A3 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
AU2003272285A8 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
TW200504078A (en) | Therapeutically active compounds and their use | |
NO2016007I2 (no) | Susoktokog | |
TW200509937A (en) | Novel compounds and their use in therapy | |
ID26781A (id) | Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer | |
ATE185971T1 (de) | Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
WO2001026658A3 (en) | Topical nasal treatment using desloratadine | |
BR0014312A (pt) | Combinação de loteprednol e anti-histaminas | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
ZA200107689B (en) | 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders. | |
DE60322075D1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
BG106226A (en) | A blocking monoclinal antibody to vla-1 and its use for the treatment of inflammatory disorders | |
WO2003047507A3 (en) | Factor viii c2 domain variants | |
AU2002363973A1 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
DE602004014020D1 (de) | Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol | |
EP1229973A4 (en) | SWING FOR THE DISABLED | |
NZ528164A (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency | |
AU2092300A (en) | Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders | |
ZA200405173B (en) | 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence. | |
HK1044112A1 (en) | Treatment of angiogenesis dependent conditions with dextrin sulphate. | |
ITBO990629A0 (it) | Dispositivo per impianto vascolare nel trattamento percutaneo delle le sioni carotidee . | |
NO20004363D0 (no) | Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontroll forstyrrelser og autisme |